RE:Just to be clear Porky ...MrMugsy wrote:
Knight Therapeutics
Year Revenue Net Income
2020 199,519,000 32,085,000
2019 47,461,000 18,033,000
2018 12,500,000 24,079,000
2017 8,634,000 17,244,000
2016 5,940,000 18,560,000
2015 1,037,000 34,167,000
2014 365,000 125,859,000
-----
From page 3 of the investor presentation:
So far the team is staying strong on that winning formula. Sure, Porky is right that we paid for that growth, but that's the point. We now have the foundation from shares that were sold at higher prices, bought a good asset with lots of potential and now we'll see the real work being done.
Before Biotoscana, the team was only able to search for potential acquisitions and manage the pile of cash. Now they have their crown jewel to build off of. It amazes me that so few see the changes taking place at knight. Everyone is so focused on past share price and "Goodman moves slow", etc. That' so far from the current reality. The team has put hundreds of millions of dollars to work in a matter of just under 2 years time after sitting on a massive pile of cash for about 5 years.
I'm not saying this will be the next Paladin or that they will recreate what once was. If anything that legacy is hurting them as it's the baseline expectation from the market. BUT, there is a very strong chance that they grow significantly from here. This can easily be a ten bagger over time. How much time, who the hell knows but it's likely to go higher from here.